Patient-reported Outcomes in the Treatment of Schizophrenia

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Patient-reported health economic outcomes for patients enrolled in S1543003 and S1543004 protocols

Phase 3

Solvay Pharmaceuticals